Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Knight Therapeutics Inc.
  6. News
  7. Summary
    GUD   CA4990531069

KNIGHT THERAPEUTICS INC.

(GUD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Knight Therapeutics Brief: Enters into Exclusive Supply and Distribution Agreement with NASDAQ's Incyte for Tafasitamab and Pemigatinib in Latin America

09/23/2021 | 07:33am EST


ę MT Newswires 2021
All news about KNIGHT THERAPEUTICS INC.
11/11Knight Therapeutics Reports Q3 Basic Net Loss $0.07
MT
11/11Knight Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
11/11Knight Therapeutics Reports Third Quarter 2021
AQ
11/05Notice of Knight Therapeutics Third Quarter 2021 Results Conference Call
AQ
11/04Notice of Knight Therapeutics' Third Quarter 2021 Results Conference Call
GL
11/04Notice of Knight Therapeutics' Third Quarter 2021 Results Conference Call
GL
09/23INCYTE : Signs Supply, Distribution Deal for Tafasitamab, Pemigatinib in Latin America
MT
09/23KNIGHT THERAPEUTICS : in Supply and Distribution Agreement with NASDAQ's Incyte for Tafasi..
MT
09/23KNIGHT THERAPEUTICS BRIEF : Enters into Exclusive Supply and Distribution Agreement with N..
MT
09/23INCYTE : Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with ..
AQ
More news
Financials
Sales 2021 247 M 193 M 193 M
Net income 2021 22,8 M 17,8 M 17,8 M
Net Debt 2021 - - -
P/E ratio 2021 26,5x
Yield 2021 -
Capitalization 647 M 506 M 505 M
Capi. / Sales 2021 2,62x
Capi. / Sales 2022 2,24x
Nbr of Employees 679
Free-Float 83,5%
Chart KNIGHT THERAPEUTICS INC.
Duration : Period :
Knight Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KNIGHT THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 5,30 CAD
Average target price 7,80 CAD
Spread / Average Target 47,1%
EPS Revisions
Managers and Directors
Samira Sakhia President, Chief Executive Officer & Director
Utchanah Arvind Chief Financial Officer
Jonathan Ross Goodman Executive Chairman
James Charles Gale Lead Independent Director
Robert N. Lande Independent Director
Sector and Competitors